Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional

A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT

ClinicalTrials.gov ID: NCT00751842

Public ClinicalTrials.gov record NCT00751842. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 4, 2026, 7:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, 3-Arm, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Impact of Diamyd on the Progression of Diabetes in Patients Newly Diagnosed With Type 1 Diabetes Mellitus (USA)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The intended purpose of this study was to determine whether Diamyd (rhGAD65 formulated in alum) is effective in preserving the body's own insulin producing capacity in patients recently diagnosed with type 1 diabetes. Based on results from other clinical trials with the study drug it was judged unlikely this study would meet the intended primary or secondary efficacy endpoints. Therefore the primary focus of this study was changed to ensure that safety data was available for at least 6 months following the last dose of active study drug. Thereafter the study was terminated.

Study identification

NCT ID
NCT00751842
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Diamyd Therapeutics AB
Industry
Enrollment
331 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
10 Years to 20 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2008
Primary completion
Feb 29, 2012
Completion
Jun 30, 2012
Last update posted
Oct 9, 2012

2008 – 2012

United States locations

U.S. sites
43
U.S. states
28
U.S. cities
43
Facility City State ZIP Site status
University of Arizona Tucson Arizona 85724
Arkansas Children's Hospital Research Institute Little Rock Arkansas 72202
Alex Endocrine Associates Rogers Arkansas 72758
Children's Hospital Orange County Orange California 92868
Rady Children's Hospital San Diego California 92123
Stanford University Medical Center Stanford California 94305
Barbara Davis Center for Childhood Diabetes Aurora Colorado 80045
Christina Care Research institute Newark Delaware 19713
University of Florida Gainsville Florida 32610
Nemours Children's Clinic Jacksonville Florida 32207
Miami Children's Hospital Research Institute Miami Florida 33155
University of South Florida Tampa Florida 33606
Atlanta Diabetes Associates Atlanta Georgia 30309
Rocky Mountain Diabetes and Osteoporosis Center Idaho Falls Idaho 83404
University of Iowa Hospitals and Clinicals Iowa City Iowa 52242
Mid America Diabetes Associates Wichita Kansas 67211
University of Kentucky College of Medicine Lexington Kentucky 40536
University of Louisville Research Foundation Louisville Kentucky 40202
Children's Hospital New Orleans Louisiana 70118
University of Maryland Medical Center Baltimore Maryland 21201
Tufts Medical Center Boston Massachusetts 02111
UMass Memorial Medical Center Worcester Massachusetts 01655
University of Michigan Health System Ann Arbor Michigan 48109
Alzohaili Medical Consultants Dearborn Michigan 48126
The Children's Mercy Hospital Kansas City Missouri 64108
St. Louis Children's Hospital St Louis Missouri 63110
Creighton Diabetes Center Omaha Nebraska 68131
Kathryn Eckert Reno Nevada 89502
Hackensack University Medical Center Hackensack New Jersey 07601
Morristown Memorial Hospital Morristown New Jersey 07962
Winthrop University Hospital Mineola New York 11501
Naomi Berrie Diabetes Center of Columbia University New York New York 10032
University of Rochester Rochester New York 14642
SUNY Institute for Human Performance Syracuse New York 13210
Children's Hospital Medical Center of Akron Akron Ohio 44308
University of Oklahoma, Schustermann Center Clinic Tulsa Oklahoma 74135
Children's Hospital of Pittsburgh of UPMC Pittsburgh Pennsylvania 15224
Regional Medical Clinic - Endocrinology Rapid City South Dakota 57701
LeBonheur Children's Medical Center Memphis Tennessee 38103
Cook Children's Medical Center Fort Worth Texas 76104
CHRISTUS Santa Rosa Children's Hospital San Antonio Texas 78207
Virginia Commonwealth University Richmond Virginia 23219
Benaroya Research Institute Seattle Washington 98101

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00751842, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 9, 2012 · Synced Sep 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00751842 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →